# Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease

> **NCT03036852** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 59 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** SOF/VEL

## Key facts

- **NCT ID:** NCT03036852
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-22
- **Primary completion:** 2018-08-13
- **Final completion:** 2018-11-07
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2020-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03036852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03036852, "Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03036852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*